S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)

Revance Therapeutics (RVNC) News Today

$7.35
-0.08 (-1.08%)
(As of 12/5/2023 ET)
Compare
Today's Range
$7.15
▼
$7.48
50-Day Range
$5.81
▼
$12.42
52-Week Range
$5.72
▼
$37.98
Volume
1.60 million shs
Average Volume
1.62 million shs
Market Capitalization
$645.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.33
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability
SourceHeadline
seekingalpha.com logoRevance Therapeutics: Not Even Daxxify Can Treat Investor Frown Lines
seekingalpha.com - November 29 at 12:06 PM
MarketBeat logoRevance Therapeutics, Inc. (NASDAQ:RVNC) Given Consensus Rating of "Moderate Buy" by Analysts
americanbankingnews.com - November 28 at 4:50 AM
markets.businessinsider.com logoWhat 10 Analyst Ratings Have To Say About Revance Therapeutics
markets.businessinsider.com - November 22 at 3:49 PM
markets.businessinsider.com logoRevance Therapeutics Maintains Buy Rating Despite Decreased Share Value: New Pricing Strategy Shows Promising Results
markets.businessinsider.com - November 10 at 8:42 AM
markets.businessinsider.com logoRevance Therapeutics: Adapting Strategy and Promising Outlook Justify Buy Rating
markets.businessinsider.com - November 10 at 8:42 AM
finance.yahoo.com logoAnalysts Just Slashed Their Revance Therapeutics, Inc. (NASDAQ:RVNC) EPS Numbers
finance.yahoo.com - November 10 at 8:42 AM
finance.yahoo.com logoRevance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 9 at 8:12 PM
finance.yahoo.com logoQ3 2023 Revance Therapeutics Inc Earnings Call
finance.yahoo.com - November 9 at 10:11 AM
finance.yahoo.com logoRevance Therapeutics, Inc. (RVNC) Reports Q3 Earnings: What Key Metrics Have to Say
finance.yahoo.com - November 8 at 11:54 PM
finance.yahoo.com logoRevance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics
finance.yahoo.com - November 8 at 6:53 PM
finance.yahoo.com logoRevance Reports Third Quarter 2023 Financial Results, Provides Corporate Update
finance.yahoo.com - November 8 at 6:53 PM
finance.yahoo.com logoRevance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
finance.yahoo.com - November 1 at 8:39 AM
finance.yahoo.com logoDAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions
finance.yahoo.com - October 26 at 8:26 AM
msn.com logoBarclays Maintains Revance Therapeutics (RVNC) Overweight Recommendation
msn.com - October 24 at 6:33 PM
marketbeat.com logoRevance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by Allspring Global Investments Holdings LLC
marketbeat.com - October 2 at 6:42 AM
marketbeat.com logoDaymark Wealth Partners LLC Invests $354,000 in Revance Therapeutics, Inc. (NASDAQ:RVNC)
marketbeat.com - October 1 at 5:50 AM
247wallst.com logoGoldman Sachs Maintains Revance Therapeutics Buy Recommendation
247wallst.com - September 22 at 2:00 PM
marketbeat.com logoRevance Therapeutics, Inc. (NASDAQ:RVNC) to Post Q3 2023 Earnings of ($1.43) Per Share, William Blair Forecasts
marketbeat.com - September 22 at 6:48 AM
benzinga.com logoDiscontinuation Of Opul Business Weighs On Botox Rival Revance Therapeutics: Analyst Sees Non-Cash Impairment Charge In Millions
benzinga.com - September 20 at 3:01 PM
marketbeat.com logoDnB Asset Management AS Buys 7,410 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC)
marketbeat.com - September 20 at 4:36 AM
seekingalpha.com logoRevance down 16% as investor day update fails to impress
seekingalpha.com - September 19 at 9:04 PM
markets.businessinsider.com logoWhat's Going On With Botox Rival Revance Therapeutics' Stock Today?
markets.businessinsider.com - September 19 at 4:04 PM
finance.yahoo.com logoRevance Provides Corporate Update at Investor Day
finance.yahoo.com - September 19 at 9:31 AM
marketbeat.com logoHarbor Capital Advisors Inc. Buys Shares of 31,692 Revance Therapeutics, Inc. (NASDAQ:RVNC)
marketbeat.com - September 19 at 6:38 AM
markets.businessinsider.com logoAnalysts Have Conflicting Sentiments on These Healthcare Companies: Revance Therapeutics (RVNC) and PTC Therapeutics (PTCT)
markets.businessinsider.com - September 18 at 9:00 AM
msn.com logoRevance Therapeutics: Impressive Sales Growth/Concerning Cash Burn
msn.com - September 15 at 7:11 PM
seekingalpha.com logoRevance's FDA Nod: Beauty, Brains, And Balance Sheets
seekingalpha.com - September 15 at 11:34 AM
marketbeat.com logoNew England Research & Management Inc. Buys Shares of 8,875 Revance Therapeutics, Inc. (NASDAQ:RVNC)
marketbeat.com - September 15 at 7:26 AM
marketbeat.com logoGranahan Investment Management LLC Decreases Stake in Revance Therapeutics, Inc. (NASDAQ:RVNC)
marketbeat.com - September 11 at 5:40 AM
marketbeat.com logoWellington Management Group LLP Has $36.76 Million Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC)
marketbeat.com - September 8 at 4:59 AM
marketbeat.com logoRoyal Capital Wealth Management LLC Buys New Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC)
marketbeat.com - September 7 at 11:58 AM
finance.yahoo.com logoRevance Therapeutics (RVNC): A Smart Investment or a Value Trap? An In-Depth Exploration
finance.yahoo.com - September 6 at 6:33 PM
marketbeat.com logoRussell Investments Group Ltd. Trims Stock Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC)
marketbeat.com - September 1 at 4:21 AM
marketbeat.com logoCredit Suisse AG Buys 8,841 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC)
marketbeat.com - August 31 at 4:58 AM
marketbeat.com logoPictet Asset Management SA Makes New $379,000 Investment in Revance Therapeutics, Inc. (NASDAQ:RVNC)
marketbeat.com - August 30 at 4:52 AM
finance.yahoo.com logoRevance to Host Investor Day on September 19, 2023
finance.yahoo.com - August 22 at 6:09 PM
finance.yahoo.com logo‘Load Up,’ Says Goldman Sachs About These 2 ‘Strong Buy’ Stocks
finance.yahoo.com - August 22 at 6:09 PM
finance.yahoo.com logoRevance Therapeutics (RVNC) Shares Declined on Profit-Taking
finance.yahoo.com - August 21 at 4:22 AM
marketbeat.com logoConnor Clark & Lunn Investment Management Ltd. Purchases New Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC)
marketbeat.com - August 20 at 5:33 AM
marketbeat.com logoBfsg LLC Has $763,000 Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)
marketbeat.com - August 18 at 10:01 AM
msn.com logoExane BNP Paribas Upgrades Revance Therapeutics (RVNC)
msn.com - August 16 at 12:16 PM
markets.businessinsider.com logoGoldman Sachs Sticks to Its Buy Rating for Revance Therapeutics (RVNC)
markets.businessinsider.com - August 14 at 10:52 PM
marketbeat.com logoEvolutionary Tree Capital Management LLC Decreases Stock Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC)
marketbeat.com - August 11 at 10:08 PM
marketbeat.com logoFY2023 Earnings Estimate for Revance Therapeutics, Inc. Issued By William Blair (NASDAQ:RVNC)
marketbeat.com - August 11 at 10:00 AM
msn.com logoMorgan Stanley Maintains Revance Therapeutics (RVNC) Equal-Weight Recommendation
msn.com - August 10 at 8:58 AM
benzinga.com logoLooking At Revance Therapeutics's Recent Unusual Options Activity
benzinga.com - August 9 at 7:47 PM
benzinga.com logoWhere Revance Therapeutics Stands With Analysts
benzinga.com - August 9 at 2:39 PM
marketbeat.com logoRevance Therapeutics (NASDAQ:RVNC) Price Target Lowered to $40.00 at Needham & Company LLC
marketbeat.com - August 9 at 11:40 AM
markets.businessinsider.com logoMizuho Securities Remains a Buy on Revance Therapeutics (RVNC)
markets.businessinsider.com - August 9 at 8:12 AM
marketbeat.com logoRevance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by Barclays PLC
marketbeat.com - August 9 at 6:32 AM
Get Revance Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.



RVNC Media Mentions By Week

RVNC Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RVNC
News Sentiment
▼
1.07

0.51
▲
Average
Medical
News Sentiment

RVNC News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RVNC Articles
This Week
▼
1

3
▲
RVNC Articles
Average Week

Get Revance Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:RVNC) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -